Related Experiment Video
Updated: Nov 25, 2025
09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
9.4K
COVID-19 and thrombosis: From bench to bedside
Mohammad A M Ali1, Sarah A Spinler2
1Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York- Binghamton, NY, USA.
Trends in Cardiovascular Medicine
|December 18, 2020
Summary
Coronavirus disease 2019 (COVID-19) increases the risk of blood clots. This review examines COVID-19
Area of Science:
- Cardiology
- Infectious Diseases
- Hematology
Background:
- COVID-19, a respiratory illness caused by SARS-CoV-2, is linked to increased risk of venous and arterial thromboembolic events.
- The association between COVID-19 and thrombosis is a significant area of scientific interest.
- Understanding this link is crucial for patient management and treatment strategies.
Purpose of the Study:
- To review current knowledge on the association between COVID-19 and thrombosis.
- To explore molecular and cellular mechanisms underlying COVID-19-associated thrombosis.
- To evaluate antithrombotic agents in COVID-19 management and discuss clinical guidelines.
Main Methods:
- Literature review of studies investigating COVID-19 and thromboembolic events.
- Analysis of molecular and cellular pathways implicated in COVID-19 pathogenesis and thrombosis.
- Review of clinical trials and guidelines concerning antithrombotic therapies in COVID-19 patients.
Main Results:
- COVID-19 significantly elevates the risk of both venous and arterial thrombosis.
- Multiple molecular and cellular mechanisms contribute to the prothrombotic state in COVID-19.
- Various antithrombotic agents show potential, with ongoing research and evolving clinical recommendations.
Conclusions:
- COVID-19 presents a substantial thrombotic risk requiring careful management.
- Further research into underlying mechanisms and effective antithrombotic strategies is essential.
- Adherence to updated professional guidelines is critical for preventing and treating thromboembolism in COVID-19.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
132
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
132
01:29Venous Thrombosis III: Interprofessional Care
124
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
124
01:30Venous Thrombosis I: Introduction
129
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
129
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
127
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
127